

IFW

Attorney Docket No. 00063.01R

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: HALE, *ET AL.*

SERIAL NO.: 10/719,540

FILED: NOVEMBER 20, 2003

TITLE: METHOD FOR TREATING PAIN  
WITH LOXAPINE AND AMOXAPINE

EXAMINER:

ART UNIT: 1614

CONFIRMATION NO.: 3439

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies of required documents enclosed, which may be material to examination of the above identified application. In accordance with 37 CFR § 1.98(a)(3)(i) the relevance of CH 436297 A is set forth in its abstract, the English translation of which is provided.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

37 CFR 1.8

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 6/22/05.

Signature: 

Name: Denise S. Magee

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.


Respectfully submitted,

Date: June 22, 2005

Darla G. Yoerg

Darla G. Yoerg, #48,056  
Swanson & Bratschun, L.L.C.  
1745 Shea Center Drive, Suite 330  
Highlands Ranch, Colorado 80129  
303-268-0066 Telephone  
303-268-0065 Facsimile

cc: W. Leschensky  
S:\CLIENTFOLDERS\ALEXZA\64.01R\IDS WITHOUT OPTIONS.DOC



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 1 of 1	ATTY. DOCKET NO. 00063.01R	SERIAL NO. 10/719,540
	APPLICANT HALE, <i>ET AL.</i>	
	FILING DATE NOVEMBER 20, 2003	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA	6,479,074	11/12/02	WILLIAMS ET AL.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	AI	WO 02/060870	08/08/02	PCT			
	AJ	WO 02/094236	11/28/02	PCT			
	AK	WO 02/102297	12/27/02	PCT			
	AL	CH 436 297 A	05/31/67	SWITZERLAND and English Abstract			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AM	Rapoport et al. (1997) CNS Drugs 7(1):37-46
	AR	
	AO	
	AP	
	AQ	
	AR	
	AS	
	AT	
	AU	
	AV	
	AW	
	AX	
	AAA	
	AAA	
	AAC	
	AAA	
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		